1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > U.S. General Anesthesia Drugs Market by Molecule, route of administration, Supply Chain, Competitive - Analysis Forecast to 2020

The report segments the U.S. general anesthesia drugs market on the basis of molecule and route of administration. On the basis of molecules, the market is divided into Propofol, Benzodiazepine, Ketamine (S-(+)-Ketamine HCL), and Methohexital Sodium. Propofol is expected to be fastest-growing segment, owing to its greater preference and rapid onset of action.

On the basis of route of administration, the U.S. general anesthesia drugs market is bifurcated into intravenous and inhalational. The intravenous segment is expected to account for the largest share of the U.S. general anesthesia drugs market in 2015. Greater patient compliance and less number of side effects as compared to inhalational anesthetics are driving the growth of this market.

Acquisitions was the most preferred strategy adopted by major industry players in order to increase their market shares and cater to unmet needs.

This report provides insights on the qualitative data, market size, growth of various segments and subsegments, and prominent players in this market. The qualitative data covers various levels of industry analysis such as market dynamics (drivers, restraints, opportunities, and threats). The report also offers market sizes and data on the growth of various segments in the industry. It focuses on emerging and high-growth segments, high-growth regions, and government initiatives. The report also provides a company profiles section, which comprises basic views on the key players in the U.S. general anesthesia drugs market and their product portfolios, developments, and strategies adopted to maintain and increase their market shares. The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographical focus, change in approach, R&D investments for innovations in products and technologies, and levels of output in order to remain successful.

Reasons to Buy the Report:
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms, garner a greater market share. Firms purchasing the report can use any one or a combination of the below-mentioned three strategies (market penetration, competitive assessment, and market entry).

The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on product portfolios of the top players in the U.S. general anesthesia drugs market. The report analyzes the U.S. general anesthesia drugs market by molecule and mode of administration.
- Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the U.S. general anesthesia drugs market
- Market Entry: Comprehensive information about business strategies for entering the U.S. general anesthesia drugs market

Table Of Contents

U.S. General Anesthesia Drugs Market by Molecule, route of administration, Supply Chain, Competitive - Analysis Forecast to 2020
TABLE OF CONTENTS

1 INTRODUCTION 12
1.1 OBJECTIVES OF THE STUDY 12
1.2 MARKET DEFINITION 12
1.3 MARKET SCOPE 12
1.3.1 YEARS CONSIDERED FOR THE STUDY 12
1.4 CURRENCY 13
1.5 STAKEHOLDERS 13
2 RESEARCH METHODOLOGY 14
2.1 MARKET SIZE ESTIMATION 15
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 17
2.2.1 KEY DATA FROM SECONDARY SOURCES 19
2.2.2 KEY DATA FROM PRIMARY SOURCES 19
2.2.3 KEY INDUSTRY INSIGHTS 20
2.3 ASSUMPTIONS FOR THE STUDY 20
3 MARKET OVERVIEW 21
3.1 MARKET ANALYSIS 21
3.2 MARKET DYNAMICS 22
3.2.1 DRIVERS 22
3.2.1.1 Rapid rise in ageing population 22
3.2.1.2 Rising prevalence of cardiovascular and respiratory system-related diseases 22
3.2.1.3 Rising number of emergency surgeries 23
3.2.2 RESTAINTS 24
3.2.2.1 Side effects associated with general anesthetic usage 24
3.2.2.2 Regulatory issues 24
3.2.3 OPPORTUNITIES 25
3.2.3.1 Patent expiry of Lusedra 25
3.3 MARKET SIZE 26
3.3.1 HISTORICAL MARKET TRENDS, 2010-2014 26
3.3.2 MARKET FORECASTS, 2015-2020 27
4 DISTRIBUTION STRUCTURE 28
4.1 U.S. KETAMINE MARKET: DISTRIBUTION STRUCTURE 28
4.2 U.S. KETAMINE MARKET, 2010-2014 30
4.2.1 U.S. KETAMINE MARKET, BY MANUFACTURER 30
4.2.2 U.S. KETAMINE MARKET, BY DISTRIBUTION CHANNEL 32
4.2.2.1 Group Purchasing Organizations (GPOs) 32
4.2.2.2 Distributors 34
4.3 MAJOR LEGAL TRENDS FOR CONTROLLED SUBSTANCES 36
4.3.1 COMPLIANCE ASSOCIATED WITH MANUFACTURING OF NARCOTICS IN THE U.S. 36
4.3.1.1 Registration 36
4.3.1.2 Security 37
4.3.1.3 Labeling and packaging 37
4.3.1.4 Inventory 37
4.3.1.5 Records 37
4.3.2 COMPLIANCE ASSOCIATED WITH VENDORS OF NARCOTICS IN THE U.S. 37
4.4 PRODUCT CATEGORY ENUMERATION 38
4.4.1 KETAMINE 38
4.4.2 OTHER BRANDS 39
4.5 MARKET SHARE, 2010-2014 40
4.5.1 MARKET SHARE, BY KEY PRODUCT 40
4.5.2 MARKET SHARE, BY KEY PLAYER 40
5 PRODUCT ANALYSIS 41
5.1 ANESTHESIA DRUGS MARKET SEGMENTATION IN THE U.S. 42
5.1.1 GENERAL ANESTHESIA DRUGS MARKET SEGMENTATION 45
5.2 U.S.: MARKET SHARE, GENERAL ANESTHETICS, 2010-2014 46
5.2.1 MAJOR BRANDS/MOLECULES 47
5.2.1.1 Propofol 47
5.2.1.2 Benzodiazepines 47
5.2.1.3 Methohexital Sodium 47
5.3 COMPETITION IN THE U.S. 48
5.3.1 KEY COMPETITORS 49
5.3.2 PRICE 50
5.3.3 MAJOR BRANDS 54
5.4 LOCAL SALES PRICE 56
5.4.1 MANUFACTURER PRICE OF KETAMINE 56
5.5 POTENTIAL BUYERS IN THE U.S. 56
5.5.1 POTENTIAL BUYERS, BY STATE 56
6 U.S. GENERAL ANESTHESIA DRUGS MARKET: KEY INFORMATION 58
6.1 IMPORT and EXPORT SYSTEMS IN THE U.S. 58
6.1.1 IMPORT OF CONTROLLED SUBSTANCES 58
6.1.1.1 Shipment of controlled substances 58
6.1.1.2 Applicants for import and export of controlled substances 58
6.1.2 EXPORT OF CONTROLLED SUBSTANCES 59
6.1.2.1 Exception for exportation for special scientific purposes 60
6.1.3 BASED ON TARIFFS 60
6.1.3.1 Custom tariff for import 61
6.1.4 BASED ON TRANSPORT 62
6.1.5 CUSTOMS CLEARANCE 62
6.1.6 NON-TARIFF BARRIERS 67
6.2 TOP RELATED EXHIBITIONS 69
6.3 DESCRIPTION OF POTENTIAL BUYERS 70
7 STRATEGIC RECOMMENDATIONS FOR ENTERING THE U.S. GENERAL ANESTHESIA DRUGS MARKET 72
8 COMPANY PROFILES 74
8.1 INTRODUCTION 74
8.2 ABBOTT LABORATORIES 75
8.3 ASTRAZENECA PLC 76
8.4 BAXTER INTERNATIONAL INC. 77
8.5 HIKMA PHARMACEUTICALS PLC 78
8.6 MYLAN N.V. 80
8.7 EISAI CO., LTD. 81
8.8 FRESENIUS SE and CO. KGAA 82
8.9 HOSPIRA, INC. 84
8.10 PAR PHARMACEUTICAL COMPANIES, INC. 85
*Details On Financials, Products and Services, Key Strategy, and Recent Developments Might Not Be Captured In Case Of Unlisted Companies.
9 APPENDIX 87
9.1 INSIGHTS OF INDUSTRY EXPERTS 87
9.2 DISCUSSION GUIDE 88
9.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 90
9.4 AVAILABLE CUSTOMIZATIONS 91
9.5 REGULATIONS FOR CONTROLLED SUBSTANCES IN THE U.S. 92
9.6 RELATED REPORTS 126


LIST OF TABLES

TABLE 1 AGEING POPULATION AND RISING NUMBER OF EMERGENCY SURGERIES TO DRIVE THE U.S. GENERAL ANESTHESIA DRUGS MARKET 23
TABLE 2 SIDE EFFECTS OF GENERAL ANESTHETICS AND REGULATORY ISSUES TO HINDER MARKET GROWTH 24
TABLE 3 PATENT EXPIRY OF LUSEDRA OFFER SIGNIFICANT GROWTH OPPORTUNITIES
FOR THE MARKET PLAYERS 25
TABLE 4 U.S.: KETAMINE MARKET SIZE, BY DISTRIBUTION CHANNEL,
2010-2014 (USD MILLION) 29
TABLE 5 U.S.: KETAMINE MARKET SIZE, BY DISTRIBUTION CHANNEL,
2015-2020 (USD MILLION) 29
TABLE 6 U.S.: KETAMINE MARKET SIZE, BY MANUFACTURER, 2010-2014 (USD MILLION) 30
TABLE 7 U.S.: KETAMINE MARKET SIZE, BY MANUFACTURER, 2010-2014 (KILOGRAM) 30
TABLE 8 U.S.: KETAMINE MARKET SIZE, BY MANUFACTURER, 2015-2020 (USD MILLION) 31
TABLE 9 U.S.: KETAMINE MARKET SIZE, BY MANUFACTURER, 2015-2020 (KILOGRAM) 31
TABLE 10 U.S.: KETAMINE MARKET SIZE, BY GPO, 2010-2014 (USD MILLION) 32
TABLE 11 U.S.: KETAMINE MARKET SIZE, BY GPO, 2010-2014 (KILOGRAM) 33
TABLE 12 U.S. KETAMINE MARKET SIZE, BY GPO, 2015-2020 (USD MILLION) 33
TABLE 13 U.S.: KETAMINE MARKET SIZE, BY GPO, 2015-2020 (KILOGRAM) 34
TABLE 14 U.S.: KETAMINE MARKET SIZE, BY DISTRIBUTOR, 2010-2014 (USD MILLION) 35
TABLE 15 U.S.: KETAMINE MARKET SIZE, BY DISTRIBUTOR, 2010-2014 (KILOGRAM) 35
TABLE 16 U.S.: KETAMINE MARKET SIZE, BY DISTRIBUTOR, 2015-2020 (USD MILLION) 35
TABLE 17 U.S.: KETAMINE MARKET SIZE, BY DISTRIBUTOR, 2015-2020 (KILOGRAM) 36
TABLE 18 ANESTHESIA DRUGS MARKET SIZE, BY TYPE, 2010-2014 (USD MILLION) 44
TABLE 19 ANESTHESIA DRUGS MARKET SIZE, BY TYPE, 2015-2020 (USD MILLION) 44
TABLE 20 U.S. ANESTHESIA DRUGS MARKET SIZE, BY TYPE, 2010-2014 (USD MILLION) 44
TABLE 21 U.S. ANESTHESIA DRUGS MARKET SIZE, BY TYPE, 2015-2020 (USD MILLION) 45
TABLE 22 U.S. GENERAL ANESTHESIA DRUGS MARKET SIZE, BY TYPE,
2010-2014 (USD MILLION) 46
TABLE 23 KETAMINE: MAJOR COMPETITOR BRANDS and MOLECULES 47
TABLE 24 U.S. GENERAL INTRAVENOUS ANESTHESIA DRUGS MARKET SIZE, BY MOLECULE, 2010-2014 (USD MILLION) 49
TABLE 25 U.S. GENERAL INTRAVENOUS ANESTHESIA DRUGS MARKET SIZE, BY MOLECULE, 2015-2020 (USD MILLION) 49
TABLE 26 KETAMINE: PRICE, 2012 (USD) 50
TABLE 27 METHOHEXITAL SODIUM PRICE, 2012 (USD) 50
TABLE 28 FOSPROPOFOL DISODIUM PRICE, 2012 (USD) 50
TABLE 29 PENTOBARBITAL SODIUM PRICE, 2012 (USD) 50
TABLE 30 PROPOFOL PRICE, 2012 (USD) 51
TABLE 31 MIDAZOLAM PRICE, 2012 (USD) 51
TABLE 32 ETOMIDATE SODIUM PRICE, 2012 (USD) 53
TABLE 33 TOTAL PER STUDY COST OF CLINICAL TRIALS, BY PHASE, (USD MILLION) 53
TABLE 34 KETAMINE PRICE, 2012 (USD) 53
TABLE 35 GENERAL INTRAVENOUS ANESTHESIA DRUGS: USAGE TRENDS 54
TABLE 36 U.S.: TOP ABUSED PRESCRIPTION DRUGS, 2013 54
TABLE 37 MANUFACTURER PRICE OF KETAMINE, 2012 56
TABLE 38 GROUP PURCHASING ORGANIZATIONS, BY STATE 56
TABLE 39 DISTRIBUTORS, BY STATE 57
TABLE 40 HARMONIZED TARIFF SCHEDULE FOR ANESTHESIA DRUGS 61
TABLE 41 ANESTHESIA MOLECULES: CHEMICAL ABSTRACTS SERVICES (CAS) NUMBERS 62
TABLE 42 REGULATORY REQUIREMENTS FOR CONTROLLED SUBSTANCES 68
TABLE 43 ANESTHESIA EXHIBITIONS 69
TABLE 44 POTENTIAL GROUP PURCHASING ORGANIZATIONS 70
TABLE 45 POTENTIAL DISTRIBUTORS 71



LIST OF FIGURES

FIGURE 1 RESEARCH DESIGN: U.S. GENERAL ANESTHESIA DRUGS MARKET 14
FIGURE 2 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 16
FIGURE 3 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 16
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND COUNTRY/REGION 17
FIGURE 5 DATA TRIANGULATION METHODOLOGY 18
FIGURE 6 GROWING BASE OF AGEING POPULATION AND RISING PREVALENCE OF CARDIOVASCULAR AND RESPIRATORY DISEASES TO BOOST THE GROWTH OF U.S. GENERAL ANESTHESIA DRUGS MARKET 22
FIGURE 7 U.S. KETAMINE MARKET SIZE, 2010 VS. 2014 (USD MILLION) 25
FIGURE 8 U.S. KETAMINE MARKET SIZE, BY ITEM, 2010 VS. 2014 (USD MILLION) 26
FIGURE 9 U.S. KETAMINE MARKET SIZE, 2010-2014 (USD MILLION) 26
FIGURE 10 U.S. KETAMINE MARKET SIZE, 2015-2020 (USD MILLION) 27
FIGURE 11 DISTRIBUTION STRUCTURE 28
FIGURE 12 U.S. KETAMINE MARKET SHARE, BY GPO (2014) 32
FIGURE 13 U.S. KETAMINE MARKET SHARE, BY DISTRIBUTOR (2014) 34
FIGURE 14 U.S. KETAMINE MARKET SIZE, BY BRAND, 2010-2014 (USD MILLION) 39
FIGURE 15 U.S. KETAMINE MARKET SHARE, BY KEY PRODUCT, 2010 VS. 2014 40
FIGURE 16 U.S. KETAMINE MARKET SHARE, BY KEY PLAYER, 2010 VS. 2014 40
FIGURE 17 ANESTHETICS MARKET SEGMENTATION 42
FIGURE 18 LOCATION QUOTIENT OF ANESTHESIA SPECIALISTS IN THE U.S., BY STATE
(MAY 2014) 43
FIGURE 19 ANESTHESIA LANDSCAPE 43
FIGURE 20 GENERAL ANESTHETICS LANDSCAPE 45
FIGURE 21 MARKET SIZE, BY MOLECULE, 2010 and 2020 (USD MILLION) 46
FIGURE 22 PROPERTIES OF INTRAVENOUS ANESTHESIA DRUGS 48
FIGURE 23 GENERAL INTRAVENOUS ANESTHESIA DRUGS MARKET SIZE, BY MOLECULE,
2014 (USD MILLION) 48
FIGURE 24 CUSTOM CLEARANCE PROCEDURE FOR IMPORT OF CONTROLLED SUBSTANCES IN THE U.S. 64
FIGURE 25 EXPORT CUSTOMS CLEARANCE PROCEDURE FOR CONTROLLED SUBSTANCES IN THE U.S. 66
FIGURE 26 BUSINESS STRATEGY 72
FIGURE 27 GEOGRAPHIC REVENUE MIX OF THE TOP THREE MARKET PLAYERS 74
FIGURE 28 ABBOTT LABORATORIES: COMPANY SNAPSHOT 75
FIGURE 29 ASTRAZENECA PLC: COMPANY SNAPSHOT 76
FIGURE 30 BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT 77
FIGURE 31 HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT 78
FIGURE 32 MYLAN N.V.: COMPANY SNAPSHOT 80
?
FIGURE 33 EISAI CO., LTD.: COMPANY SNAPSHOT 81
FIGURE 34 FRESENIUS SE and CO. KGAA: COMPANY SNAPSHOT 82
FIGURE 35 HOSPIRA, INC.: COMPANY SNAPSHOT 84
FIGURE 36 PAR PHARMACEUTICAL COMPANIES, INC.: COMPANY SNAPSHOT 85

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Sufentanil Citrate Market: By Applications (Surgery, Epidural Anaesthesia and Medicinal Application) & By Geography (North America, Europe, Asia Pacific & Rest of the World (RoW))-Forecast (2016-2021)

Sufentanil Citrate Market: By Applications (Surgery, Epidural Anaesthesia and Medicinal Application) & By Geography (North America, Europe, Asia Pacific & Rest of the World (RoW))-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Sufentanil, also known as R30730 or brand name Sufenta, is a synthetic opioid analgesic drug which is considerably more potent than its parent drug, fentanyl, morphine. It is used for producing anesthesia ...

Global General Anesthesia Drugs Market - Growth, Trends, and Forecasts (2016 - 2021)

Global General Anesthesia Drugs Market - Growth, Trends, and Forecasts (2016 - 2021)

  • $ 4250
  • Industry report
  • October 2016
  • by Mordor Intelligence LLP

The global general anesthesia drugs market accounted for USD 3,840 million in 2015 and USD 3,983 million in 2016. The market is expected to reach USD 4,760 million by 2021, growing at a CAGR of 3.6% during ...

Global Local Anesthesia Drugs Market - Growth, Trends, and Forecasts (2016 - 2021)

Global Local Anesthesia Drugs Market - Growth, Trends, and Forecasts (2016 - 2021)

  • $ 4250
  • Industry report
  • October 2016
  • by Mordor Intelligence LLP

The global local anesthesia drugs market accounted for USD 8,160 million in 2015 and USD 8,335 million in 2016. The market is expected to reach USD 9,240 million by 2021, growing at a CAGR of 2.1% during ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.